Synoviolin CRISPR/Cas9 KO Plasmid (h): sc-403476
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Synoviolin CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Synoviolin genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Synoviolin Antibody (4H4): sc-293484
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Synoviolin CRISPR/Cas9 KO Plasmid (h) | sc-403476 | 20 µg | $397.00 |
Overview
Human SYVN1 encodes synoviolin, an endoplasmic reticulum (ER)-resident RING-type E3 ubiquitin ligase that functions as a core component of ER-associated degradation (ERAD) to ubiquitinate misfolded proteins and promote proteasomal clearance. Through ER protein quality control, synoviolin helps maintain proteostasis and modulates unfolded protein response signaling, linking ER stress to downstream inflammatory and survival pathways. SYVN1 activity has been connected to regulation of apoptosis and cell-cycle control via ubiquitin-dependent turnover of key substrates, influencing cellular adaptation to chronic stress. Dysregulated SYVN1 expression or ERAD capacity is implicated in disease-relevant mechanisms including synovial hyperplasia and inflammatory joint pathology, as well as broader contexts of proteostasis imbalance.
Synoviolin CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SYVN1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SYVN1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SYVN1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Synoviolin protein expression.
This CRISPR knockout system enables efficient generation of SYVN1-deficient cell models for investigation of Synoviolin signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SYVN1 exon(s) critical for Synoviolin function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SYVN1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Synoviolin CRISPR/Cas9 KO Plasmid (h) and Synoviolin CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SYVN1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Synoviolin HDR Plasmid (h) and Synoviolin HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SYVN1 homology arms to support homology-directed repair at defined SYVN1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.